Cormorant Asset Management as of March 31, 2015
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 71 positions in its portfolio as reported in the March 2015 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Receptos | 9.9 | $64M | 390k | 164.89 | |
Alkermes (ALKS) | 6.6 | $43M | 700k | 60.97 | |
Puma Biotechnology (PBYI) | 6.1 | $40M | 167k | 236.11 | |
Eagle Pharmaceuticals (EGRX) | 4.6 | $30M | 717k | 41.89 | |
Bristol Myers Squibb (BMY) | 4.6 | $30M | 459k | 64.50 | |
Neurocrine Biosciences (NBIX) | 4.4 | $29M | 719k | 39.71 | |
Portola Pharmaceuticals | 3.4 | $22M | 575k | 37.96 | |
Dyax | 3.0 | $19M | 1.1M | 16.75 | |
Sorrento Therapeutics (SRNE) | 3.0 | $19M | 1.7M | 11.56 | |
Quotient | 2.9 | $19M | 1.1M | 17.00 | |
Heron Therapeutics (HRTX) | 2.9 | $19M | 1.3M | 14.55 | |
Ovascience | 2.5 | $16M | 463k | 34.73 | |
Regulus Therapeutics | 2.4 | $15M | 897k | 16.94 | |
Advaxis | 2.2 | $14M | 975k | 14.44 | |
Ardelyx (ARDX) | 2.0 | $13M | 1.0M | 13.09 | |
Tesaro | 1.7 | $11M | 191k | 57.40 | |
Keryx Biopharmaceuticals | 1.6 | $11M | 826k | 12.73 | |
Novavax | 1.6 | $10M | 1.2M | 8.27 | |
Dex (DXCM) | 1.5 | $9.5M | 153k | 62.34 | |
Karyopharm Therapeutics (KPTI) | 1.4 | $9.2M | 301k | 30.61 | |
Alder Biopharmaceuticals | 1.4 | $9.2M | 318k | 28.86 | |
Chimerix (CMRX) | 1.3 | $8.6M | 230k | 37.69 | |
Omeros Corporation (OMER) | 1.3 | $8.6M | 389k | 22.03 | |
Epirus Biopharmaceuticals In | 1.2 | $8.0M | 897k | 8.95 | |
Pfenex | 1.2 | $7.6M | 475k | 15.94 | |
China Biologic Products | 1.1 | $7.3M | 77k | 95.52 | |
Agenus | 1.1 | $7.2M | 1.4M | 5.13 | |
Forward Pharma A/s | 1.1 | $7.2M | 255k | 28.32 | |
Sangamo Biosciences (SGMO) | 1.1 | $6.9M | 442k | 15.68 | |
Coherus Biosciences (CHRS) | 1.0 | $6.7M | 219k | 30.58 | |
Acceleron Pharma | 1.0 | $6.5M | 170k | 38.06 | |
Curis | 1.0 | $6.3M | 2.6M | 2.40 | |
Ultragenyx Pharmaceutical (RARE) | 1.0 | $6.3M | 102k | 62.09 | |
Array BioPharma | 1.0 | $6.3M | 850k | 7.37 | |
BioCryst Pharmaceuticals (BCRX) | 0.9 | $6.1M | 680k | 9.03 | |
Recro Pharma | 0.9 | $5.9M | 656k | 9.07 | |
Aptose Biosciences | 0.9 | $5.8M | 1.1M | 5.38 | |
Kite Pharma | 0.9 | $5.8M | 100k | 57.68 | |
Minerva Neurosciences | 0.9 | $5.7M | 1.1M | 5.00 | |
Lion Biotechnologies | 0.8 | $5.1M | 425k | 12.11 | |
Epizyme | 0.8 | $5.0M | 266k | 18.78 | |
Lipocine | 0.7 | $4.6M | 667k | 6.90 | |
Nektar Therapeutics (NKTR) | 0.7 | $4.4M | 398k | 11.00 | |
Synageva Biopharma | 0.6 | $4.1M | 43k | 97.53 | |
Dicerna Pharmaceuticals | 0.6 | $4.1M | 170k | 24.03 | |
Glycomimetics (GLYC) | 0.6 | $3.8M | 459k | 8.32 | |
Genvec | 0.6 | $3.7M | 1.3M | 2.95 | |
Rockwell Medical Technologies | 0.6 | $3.7M | 340k | 10.93 | |
Cerulean Pharma | 0.6 | $3.6M | 401k | 9.01 | |
Acelrx Pharmaceuticals | 0.5 | $3.3M | 850k | 3.86 | |
Versartis | 0.5 | $3.1M | 170k | 18.37 | |
Nanostring Technologies (NSTGQ) | 0.4 | $2.8M | 275k | 10.19 | |
Dermira | 0.4 | $2.6M | 170k | 15.35 | |
Immune Design | 0.4 | $2.5M | 119k | 21.11 | |
Kindred Biosciences | 0.4 | $2.3M | 329k | 7.14 | |
Aquinox Pharmaceuticals | 0.4 | $2.3M | 280k | 8.22 | |
Agile Therapeutics | 0.3 | $1.7M | 182k | 9.27 | |
Cellectar Biosciences | 0.2 | $1.6M | 530k | 3.11 | |
Bellicum Pharma | 0.2 | $1.2M | 51k | 23.18 | |
Akebia Therapeutics (AKBA) | 0.2 | $1.1M | 100k | 11.11 | |
Ascendis Pharma A S (ASND) | 0.2 | $1.1M | 62k | 17.35 | |
Galectin Therapeutics (GALT) | 0.1 | $959k | 286k | 3.35 | |
Veracyte (VCYT) | 0.1 | $984k | 135k | 7.28 | |
Scynexis | 0.1 | $825k | 99k | 8.30 | |
Cellectis S A (CLLS) | 0.1 | $865k | 25k | 34.60 | |
Ptc Therapeutics I (PTCT) | 0.1 | $517k | 8.5k | 60.82 | |
Applied Genetic Technol Corp C | 0.1 | $520k | 26k | 19.99 | |
Cellectar Biosciences Inc *w exp 08/19/201 | 0.1 | $413k | 530k | 0.78 | |
Nevro (NVRO) | 0.1 | $407k | 8.5k | 47.88 | |
Celsus Therapeutics Plc sponsored adr ne | 0.0 | $218k | 287k | 0.76 | |
Sage Therapeutics (SAGE) | 0.0 | $43k | 850.00 | 50.59 |